Gambro expands product recall after more patients die following dialysis treatment
This article was originally published in Clinica
Gambro Healthcare has expanded its recall of blood tubing sets outside the US following the deaths of a further two patients after dialysis treatment. This brings the total number of deaths to four. The company organised the US recall of three lots of COBE Centrysystem 3 blood tubing last month after two patients died and around 30 patients became ill after treatment in clinics in Maryland, Nebraska and Massachusetts (see Clinica No 810, p 10).
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.